Histological evaluation of a “residual” metastasis after ipilimumab therapy in a patient with advanced melanoma
Shigeto Matsushita
Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
Department of Dermato-Oncology/Dermatology, National Hospital Organization Kagoshima Medical Center, Kagoshima, Japan
Search for more papers by this authorLukas Krähenbühl
Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
Search for more papers by this authorAtsushi Otsuka
Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
Search for more papers by this authorDaniela Mihic-Probst
Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
Search for more papers by this authorPhil Cheng
Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
Search for more papers by this authorReinhard Dummer
Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
Search for more papers by this authorCorresponding Author
Simone M. Goldinger
Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
Correspondence: Simone M. Goldinger, M.D., Department of Dermatology, University Hospital Zurich, 31 Gloriastrasse, Zurich CH-8091, Switzerland. Email: [email protected]Search for more papers by this authorShigeto Matsushita
Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
Department of Dermato-Oncology/Dermatology, National Hospital Organization Kagoshima Medical Center, Kagoshima, Japan
Search for more papers by this authorLukas Krähenbühl
Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
Search for more papers by this authorAtsushi Otsuka
Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
Search for more papers by this authorDaniela Mihic-Probst
Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
Search for more papers by this authorPhil Cheng
Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
Search for more papers by this authorReinhard Dummer
Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
Search for more papers by this authorCorresponding Author
Simone M. Goldinger
Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
Correspondence: Simone M. Goldinger, M.D., Department of Dermatology, University Hospital Zurich, 31 Gloriastrasse, Zurich CH-8091, Switzerland. Email: [email protected]Search for more papers by this author
References
- 1Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711–723.
- 2Wolchok JD, Weber JS, Maio M et al. Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. Ann Oncol 2013; 24: 2174–2180.
- 3Robert C, Schadendorf D, Messina M, Hodi FS, O'Day SJ; MDX010-20 investigators. Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control. Clin Cancer Res 2013; 15: 2232–2239.
- 4Tsaknakis B, Schaefer IM, Schwörer H et al. Long-lasting complete response of metastatic melanoma to ipilimumab with analysis of the resident immune cells. Med Oncol 2014; 31: 813.
- 5McDermott D, Lebbé C, Hodi FS et al. Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. Cancer Treat Rev 2014; 40: 1056–1064.
